Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTO1 CAR T Cells in Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
2024-512903-38-00Phase 2Authorised
- Sponsor
- Autolus Therapeutics plc
- Start
- Jul 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of obecabtagene autoleucel in acute lymphoblastic leukemia (ALL), sponsored by Autolus Therapeutics plc. Primary endpoints: Frequency and severity of adverse events and serious adverse events after AUTO1 infusion, Overall complete remission rate (Cohort IIA) and 1 more. Planned start Jul 2024; status: authorised.
02
Drugs
obecabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-512903-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512903-38-00.